ID: ALA382307

Max Phase: Preclinical

Molecular Formula: C25H24ClNO3S

Molecular Weight: 453.99

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCCCCCc1c(Cl)sc2nc(O)c(-c3cccc(Oc4ccccc4)c3)c(O)c12

Standard InChI:  InChI=1S/C25H24ClNO3S/c1-2-3-4-8-14-19-21-22(28)20(24(29)27-25(21)31-23(19)26)16-10-9-13-18(15-16)30-17-11-6-5-7-12-17/h5-7,9-13,15H,2-4,8,14H2,1H3,(H2,27,28,29)

Standard InChI Key:  MNBLFRBFZLPHFR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 453.99

Molecular Weight (Monoisotopic): 453.1165

AlogP: 7.94

#Rotatable Bonds: 8

Polar Surface Area: 62.58

Molecular Species: NEUTRAL

HBA: 5

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.38

CX Basic pKa:

CX LogP: 8.64

CX LogD: 8.64

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.27

Np Likeness Score: -0.30

References

1. Buchstaller HP, Siebert CD, Steinmetz R, Frank I, Berger ML, Gottschlich R, Leibrock J, Krug M, Steinhilber D, Noe CR..  (2006)  Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor.,  49  (3): [PMID:16451052] [10.1021/jm0503493]

Source

Source(1):

• Scientific Literature